About

Wayne DeVeydt became Chief Financial Officer of UnitedHealth Group in September 2025. He was previously a Managing Director at Bain Capital (2022–2025), Executive Chairman (2020–2025) and CEO (2018–2020) of Surgery Partners, and Executive Vice President and CFO of Elevance Health, formerly Anthem (2007–2016).

Earlier in his career he held roles including Chief Strategy Officer and Chief Accounting Officer at Anthem and was a partner at PricewaterhouseCoopers. He serves as a director of Centene Corporation.

Roles

Unitedhealth Group Inc.
Chief Financial Officer · Current role
2025–present
Bain Capital
Managing Director
2022–2025
Surgery Partners
Executive Chairman of the Board
2020–2025
Surgery Partners
Chief Executive Officer and Director
2018–2020
Elevance Health (formerly Anthem)
Executive Vice President and Chief Financial Officer
2007–2016
Anthem
Chief Strategy Officer, Chief Accounting Officer and Chief of Staff to the Chairman and CEO
2005–2007
PricewaterhouseCoopers
Partner

External Roles

Centene Corporation
Director
2022–Present

Fixed Compensation

FY 2025
Base salary
$284,615
Payment scheduleBi-weekly, in cash
Evaluation periodFY2025
Sign-on cash bonus
$1,200,000
Additional detailsReplaces forgone compensation; subject to clawback
Evaluation periodFY2025
All other compensation
$97,594
Insurance premiums$2,382
Executive security$95,212
Total compensation
$14,582,684
Fiscal year2025

Performance Compensation

Data from FY 2025

Cash incentive

2025 annual cash incentive award
$1,500,000
Target Opportunity
Plan2008 Executive Incentive Plan
Evaluation periodFY2025
Revenue
$461.7B target
Target Opportunity
Weighting30%
Threshold / Target / Max$438.6B / $461.7B / $484.8B
2025 adjusted resultBetween threshold and target
Evaluation periodFY2025
Operating income
$38.5B target
Target Opportunity
Weighting30%
Threshold / Target / Max$32.7B / $38.5B / $44.3B
2025 adjusted resultBelow threshold
Evaluation periodFY2025
Cash flow from operations
$32.0B target
Target Opportunity
Weighting15%
Threshold / Target / Max$27.2B / $32.0B / $36.8B
2025 adjusted resultBelow threshold
Evaluation periodFY2025
Net Promoter Score (NPS)
12.5% weighting
Target Opportunity
Weighting12.5%
2025 resultBetween threshold and target
Evaluation periodFY2025
Employee Experience Index (EXI)
12.5% weighting
Target Opportunity
Weighting12.5%
2025 resultBetween threshold and target
Evaluation periodFY2025

Stock awards

2025 long-term incentive (target value)
$6,500,000
Award mix50% performance shares / 25% stock options / 25% RSUs
RSUs + performance shares grant-date fair value$8,250,430
Stock options grant-date fair value$3,250,045
Evaluation periodFY2025
NoteIncludes pro-rated 2025 annual award plus sign-on RSU/NSO grants per his employment agreement.
Restricted stock units (RSUs)
Not disclosed
Target shares (#)10,525
Weighting25%
VestingRatable over 4 years
Grant year2025
Non-qualified stock options
$3,250,045
Options granted (#)42,551
Weighting25%
VestingRatable over 4 years
Grant year2025

Also at Unitedhealth Group Inc.

Related

See how VectorShift works for your firm

Request Demo